TLR9-mediated activation of dendritic cells by CD32 targeting for the generation of highly immunostimulatory vaccines

References

• Dzionek A, Inagaki Y, Okawa K, Nagafune J, Röck J, Sohma Y, Winkels G, Zysk M, Yamaguchi Y, Schmitz J. Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions. Hum Immunol. 2002;63(12):1133–1148. doi:10.1016/S0198-8859(02)00752-8.
   PubMed Web of Science ®Google Scholar
• Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol. 2004;5(12):1219–1226 10.1038/ni1141
   PubMed Web of Science ®Google Scholar
• Wang Y, Swiecki M, McCartney SA, Colonna M. dsRNA sensors and plasmacytoid dendritic cells in host defense and autoimmunity. Immunol Rev. 2011;243:.74–90. doi:10.1111/j.1600-065X.2011.01049.x.
   PubMed Web of Science ®Google Scholar
• Bao M, Liu YJ. Regulation of TLR7/9 signaling in plasmacytoid dendritic cells. Protein Cell. 2013;4(1):40–52. doi:10.1007/s13238-012-2104-8.
   PubMed Web of Science ®Google Scholar
• Klinman DM, Currie D, Gursel I, Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev. 2004;199:.201–216. doi:10.1111/j.0105-2896.2004.00148.x.
   PubMed Web of Science ®Google Scholar
• Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nature Immunology. 2005;6(8):769–776. doi:10.1038/ni1223.
   PubMed Web of Science ®Google Scholar
• Sittig SP, Bakdash G, Weiden J, Sköld AE, Tel J, Figdor CG, De Vries IJ, Schreibelt G. A comparative study of the T cell stimulatory and polarizing capacity of human primary blood dendritic cell subsets. Mediators Inflamm. 2016:3605643. doi:10.1155/2016/3605643
   PubMed Web of Science ®Google Scholar
• Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006;5(6):471–484. doi:10.1038/nrd2059.
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179(4):1109–1118. doi:10.1084/jem.179.4.1109.
   PubMed Web of Science ®Google Scholar
• Båve U, Magnusson M, Eloranta ML, Perers A, Alm GV, Rönnblom L. Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J Immunol. 2003;171(6):3296–3302. doi:10.4049/jimmunol.171.6.3296.
   PubMed Web of Science ®Google Scholar
• Benitez-Ribas D, Tacken P, Punt CJ, De Vries IJ, Figdor CG. Activation of human plasmacytoid dendritic cells by TLR9 impairs Fc gammaRII-mediated uptake of immune complexes and presentation by MHC class II. J Immunol. 2008;181(8):5219–5224. doi:10.4049/jimmunol.181.8.5219.
   PubMed Web of Science ®Google Scholar
• Hartmann G, Battiany J, Poeck H, Wagner M, Kerkmann M, Lubenow N, Rothenfusser S, Endres S. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J Immunol. 2003;33(6):1633–1641. doi:10.1002/eji.200323813.
   PubMed Web of Science ®Google Scholar
• Ida JA, Shrestha N, Desai S, Pahwa S, Hanekom WA, Haslett PA. A whole blood assay to assess peripheral blood dendritic cell function in response to Toll-like receptor stimulation. J Immunol Methods. 2006;310(1–2):86–99. doi:10.1016/j.jim.2005.12.008.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34–47. doi:10.1038/nri2206.
   PubMed Web of Science ®Google Scholar
• Karnell JL, Dimasi N, Karnell FG 3rd, Fleming R, Kuta E, Wilson M, Wu H, Gao C, Herbst R, Ettinger R. CD19 and CD32b differentially regulate human B cell responsiveness. J Immunol. 2014;192(4):1480–1490. doi:10.4049/jimmunol.1301361.
   PubMed Web of Science ®Google Scholar
• Tel J, Beenhakker N, Koopman G, Hart B, Mudde GC, De Vries IJ. Targeted delivery of CpG ODN to CD32 on human and monkey plasmacytoid dendritic cells augments IFNα secretion. Immunobiology. 2012;217(10):1017–1024. doi:10.1016/j.imbio.2012.01.016.
   PubMed Web of Science ®Google Scholar
• Looney RJ, Abraham GN, Anderson CL. Human monocytes and U937 cells bear two distinct Fc receptors for IgG. J Immunol. 1986;136(5):1641–1647 http://www.jimmunol.org/content/136/5/1641
   PubMed Web of Science ®Google Scholar
• Horejs-Hoeck J, Hren A, Mudde GC, Woisetschläger M. Inhibition of immunoglobulin E synthesis through Fc gammaRII (CD32) by a mechanism independent of B-cell receptor co-cross-linking. Immunology. 2005;115(3):407–415. doi:10.1111/j.1365-2567.2005.02162.x.
   PubMed Web of Science ®Google Scholar
• Chao H, Bautista DL, Litowski J, Irvin RT, Hodges RS. Use of a heterodimeric coiled-coil system for biosensor application and affinity purification. J Chromatogr B Biomed Sci Appl. 1998;715(1):307–329. doi:10.1016/S0378-4347(98)00172-8.
   PubMed Web of Science ®Google Scholar
• Reece SW, Wardle RL, Gaier S, Pichler J, Chandler J, Kravchuk AV, Sepulveda JA, Putnam BD, Katwa LC, Olmstead SG, et al. Vaccination with SG100 attenuates aeroallergen-induced early and late phase asthmatic responses in house dust mite sensitive non-human primates. In: editors, Maurer M, Behrendt H. Allergies: current challenges and solutions (Proceedings of the 30th Symposium of the Collegium Internationale Allergologicum (CIA)). Munich, Germany: Pacini Medicina Editore S.r.l.; 2016. p. 215–221. http://www.pacinimedicina.it/allergies-current-challenges-and-solutions/
   Google Scholar
• Broome P, Wardle RL, Wang X, Gaier S, Pichler J, Chandler JH, Katwa LC, Reece RC, Laing P, Mudde GC, and others. Primate study of TYG100 a novel rationally-designed recombinant vaccine for gastrin sensitive cancers: immunogenicity and tolerability in a species-homologous mode. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014. Apr 5-9; San Diego (CA. Philadelphia (PA)): AACR; Cancer Res 2014; 74(19Suppl):Abstract nr 2886. doi:10.1158/1538-7445.AM2014-2886
   Google Scholar
• Zhang X, Munegowda MA, Yuan J, Wei Y, Xiang J. Optimal TLR9 signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses. J Leukoc Biol. 2010;88(2):393–403. doi:10.1189/jlb.0909633.
   PubMed Web of Science ®Google Scholar
• Peng SL. Signaling in B cells via Toll-like receptors. Curr Opin Immunol. 2005;17(3):230–236. doi:10.1016/j.coi.2005.03.003.
   PubMed Web of Science ®Google Scholar
• Mudde GC, Van Reijsen FC, Boland GJ, De Gast GC, Bruijnzeel PL, Bruijnzeel-Koomen CA. Allergen presentation by epidermal Langerhans’ cells from patients with atopic dermatitis is mediated by IgE. Immunology. 1990;69(3):335–341 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1385948/
   PubMed Web of Science ®Google Scholar
• Santamaria LF, Bheekha R, van Reijsen FC, Perez Soler MT, Suter M, Bruijnzeel-Koomen CA, Mudde GC. Antigen focusing by specific monomeric immunoglobulin E bound to CD23 on Epstein-Barr virus-transformed B cells. Hum Immunol. 1993;37(1):23–30. doi:10.1016/0198-8859(93)90139-R.
   PubMed Web of Science ®Google Scholar
• Le GF, Kipriyanov SM, Moldenhauer G, Little M. Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding. FEBS Lett. 1999;453(1–2):164–168. doi:10.1016/S0014-5793(99)00713-9.
   PubMed Web of Science ®Google Scholar
• Chen Y, Kim MT, Zheng L, Deperalta G, Jacobson F. Structural Characterization of Cross-Linked Species in Trastuzumab Emtansine (Kadcyla). Bioconjug Chem. 2016;27(9):2037–2047. doi:10.1021/acs.bioconjchem.6b00316.
   PubMed Web of Science ®Google Scholar
• Gohda J, Matsumura T, Inoue JI. Cutting edge: TNFR-associatedfactor (TRAF) 6 is essential for MyD88-dependent pathway but not Toll/IL-1 receptor domain-containing adaptor-inducing IFN-β(TRIF)-dependent pathway in TLR signaling. J Immunology. 2004;173(5):2913–2917. doi:10.4049/jimmunol.173.5.2913.
   PubMed Web of Science ®Google Scholar
• Boltjes A, van Wijk F. Human dendritic cell functional specialization in steady-state and inflammation. Front Immunol. 2014;5:.131. doi:10.3389/fimmu.2014.00131.
   PubMed Web of Science ®Google Scholar
• Lehmann CH, Heger L, Heidkamp GF, Baranska A, Lühr JJ, Hoffmann A, Dudziak D. Direct Delivery of Antigens to Dendritic Cells via Antibodies Specific for Endocytic Receptors as a Promising Strategy for Future Therapies. Vaccines (Basel). 2016;4(2):8. doi:10.3390/vaccines4020008.
   Web of Science ®Google Scholar
• Macri C, Dumont C, Johnston AP, Mintern JD. Targeting dendritic cells: a promising strategy to improve vaccine effectiveness. Clin Transl Immunology. 2016;5(3):e66. doi:10.1038/cti.2016.6.
   PubMedGoogle Scholar
• Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, Brimnes MK, Moltedo B, Moran TM, Steinman RM. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med. 2004;199(6):815–824. doi:10.1084/jem.20032220.
   PubMed Web of Science ®Google Scholar
• Birkholz K, Schwenkert M, Kellner C, Gross S, Fey G, Schuler-Thurner B, Schuler G, Schaft N, Dörrie J. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation. Blood. 2010;116(13):2277–2285. doi:10.1182/blood-2010-02-268425.
   PubMed Web of Science ®Google Scholar
• Stoitzner P, Schaffenrath S, Tripp CH, Reider D, Komenda K, Del Frari B, Djedovic G, Ebner S, Romani N. Human skin dendritic cells can be targeted in situ by intradermal injection of antibodies against lectin receptors. Exp Dermatol. 2014;23(12):909–915. doi:10.1111/exd.12573.
   PubMed Web of Science ®Google Scholar
• Kato M, McDonald KJ, Khan S, Ross IL, Vuckovic S, Chen K, Munster D, MacDonald KP, Hart DN. Expression of human DEC-205 (CD205) multilectin receptor on leukocytes. Int Immunol. 2006;18:.857–869. doi:10.1093/intimm/dxl022.
   PubMed Web of Science ®Google Scholar
• Tacken PJ, De Vries IJ, Gijzen K, Joosten B, Wu D, Rother RP, Faas SJ, Punt CJ, Torensma R, Adema GJ; others. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood. 2005;106(4):1278–1285. doi:10.1182/blood-2005-01-0318.
   PubMed Web of Science ®Google Scholar
• Kretz-Rommel A, Qin F, Dakappagari N, Torensma R, Faas S, Wu D, Bowdish KS. vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models. J Immunother. 2007;30(7):715–726. doi:10.1097/CJI.0b013e318135472c.
   PubMed Web of Science ®Google Scholar
• Meyer-Wentrup F, Benitez-Ribas D, Tacken PJ, Punt CJ, Figdor CG, De Vries IJ, Adema GJ. Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production. Blood. 2008;111(8):4245–4253. doi:10.1182/blood-2007-03-081398.
   PubMed Web of Science ®Google Scholar
• Tullett KM, Leal Rojas IM, Minoda Y, Tan PS, Zhang JG, Smith C, Khanna R, Shortman K, Caminschi I, Lahoud MH, et al.; others. Targeting CLEC9A delivers antigen to human CD141+ DC for CD4+ and CD8+T cell recognition. JCI Insight. 2016;1(7):e87102. doi:10.1172/jci.insight.87102.
   PubMed Web of Science ®Google Scholar
• Marshall AS, Willment JA, Lin HH, Williams DL, Gordon S, Brown GD. Identification and characterization of a novel human myeloid inhibitory C-type lectin-like receptor (MICL) that is predominantly expressed on granulocytes and monocytes. J Biol Chem. 2004;279(15):14792–14802. doi:10.1074/jbc.M313127200.
   PubMed Web of Science ®Google Scholar
• Hartung E, Becker M, Bachem A, Reeg N, Jäkel A, Hutloff A, Weber H, Weise C, Giesecke C, Henn V, et al.; others. Induction of potent CD8 T cell cytotoxicity by specific targeting of antigen to cross-presenting dendritic cells in vivo via murine or human XCR1. J Immunol. 2015;194(3):1069–1079. doi:10.4049/jimmunol.1401903.
   PubMed Web of Science ®Google Scholar
• Lahoud MH, Ahmet F, Zhang JG, Meuter S, Policheni AN, Kitsoulis S, Lee CN, O’Keeffe M, Sullivan LC, Brooks AG; others. DEC-205 is a cell surface receptor for CpG oligonucleotides. Proc Natl Acad Sci USA. 2012;109:16270–16275. doi:10.1073/pnas.1208796109.
   PubMed Web of Science ®Google Scholar
• Shrimpton RE, Butler M, Morel AS, Eren E, Hue SS, Ritter MA. CD205 (DEC-205): a recognition receptor for apoptotic and necrotic self. Mol Immunol. 2009;46:.1229–1239. doi:10.1016/j.molimm.2008.11.016.
   PubMed Web of Science ®Google Scholar
• Neumann K, Castiñeiras-Vilariño M, Höckendorf U, Hannesschläger N, Lemeer S, Kupka D, Meyermann S, Lech M, Anders HJ, Kuster B; others. Clec12a is an inhibitory receptor for uric acid crystals that regulates inflammation in response to cell death. Immunity. 2014;40(3):389–399. doi:10.1016/j.immuni.2013.12.015.
   PubMed Web of Science ®Google Scholar
• Hutten TJ, Thordardottir S, Fredrix H, Janssen L, Woestenenk R, Tel J, Joosten B, Cambi A, Heemskerk MH, Franssen GM; others. CLEC12A-mediated antigen uptake and cross-presentation by human dendritic cell subsets efficiently boost tumor-reactive T cell responses. J Immunol. 2016;197(7):2715–2725. 10.4049/jimmunol.1600011.
   PubMed Web of Science ®Google Scholar
• Macagno A, Napolitani G, Lanzavecchia A, Sallusto F. Duration, combination and timing: the signal integration model of dendritic cell activation. Trends Immunol. 2007;28(5):227–233. doi:10.1016/j.it.2007.03.008.
   PubMed Web of Science ®Google Scholar
• Krug A, Veeraswamy R, Pekosz A, Kanagawa O, Unanue ER, Colonna M, Cella M. Interferon-producing cells fail to induce proliferation of naive T cells but can promote expansion and T helper 1 differentiation of antigen-experienced unpolarized T cells. J Exp Med. 2003;197(7):899–906. doi:10.1084/jem.20021091.
   PubMed Web of Science ®Google Scholar
• Fonteneau JF, Gilliet M, Larsson I, Dasilva I, Münz C, Liu YJ, Bhardwaj N. Activation of influenza virus-specific CD4+ and CD8+ T cells: a new role for plasmacytoid dendritic cells in adaptive immunity. Blood. 2003;101:.3520–3526. doi:10.1182/blood-2002-10-3063.
   PubMed Web of Science ®Google Scholar
• Langenkamp A, Nagata K, Murphy K, Wu L, Lanzavecchia A, Sallusto F. Kinetics and expression patterns of chemokine receptors in human CD4+ T lymphocytes primed by myeloid or plasmacytoid dendritic cells. Eur J Immunol. 2003;33(2):474–482. doi:10.1002/immu.200310023.
   PubMed Web of Science ®Google Scholar
• Benitez-Ribas D, Adema GJ, Winkels G, Klasen IS, Punt CJ, Figdor CG, De Vries IJ. Plasmacytoid dendritic cells of melanoma patients present exogenous proteins to CD4+ T cells after Fc gamma RII-mediated uptake. J Exp Med. 2006;203(7):1629–1635. doi:10.1084/jem.20052364.
   PubMed Web of Science ®Google Scholar
• Tel J, Aarntzen EH, Baba T, Schreibelt G, Schulte BM, Benitez-Ribas D, Boerman OC, Croockewit S, Oyen WJ, van Rossum M; others. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res. 2013;73(3):1063–1075. doi:10.1158/0008-5472.CAN-12-2583.
   PubMed Web of Science ®Google Scholar
• Stern BV, Boehm BO, Tary-Lehmann M. Vaccination with tumor peptide in CpG adjuvant protects via IFN-gamma-dependent CD4 cell immunity. J Immunol. 2002;168(12):6099–6105. doi:10.4049/jimmunol.168.12.6099.
   PubMed Web of Science ®Google Scholar
• Krishnamachari Y, Salem AK. Innovative strategies for co-delivering antigens and CpG oligonucleotides. Adv Drug Deliv Rev. 2009;61(3):205–217. doi:10.1016/j.addr.2008.12.013.
   PubMed Web of Science ®Google Scholar
• Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotný J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R; others. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA. 1988;85(16):5879–5883. doi:10.1073/pnas.85.16.5879.
   PubMed Web of Science ®Google Scholar
• Harris RJ. Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture. J Chromatogr A. 1995;705(1):129–134. doi:10.1016/0021-9673(94)01255-D.
   PubMed Web of Science ®Google Scholar